Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients
- PMID: 31704366
- DOI: 10.1016/j.humpath.2019.09.016
Intratumoral heterogeneity and loss of ARID1A expression in gastric cancer correlates with increased PD-L1 expression in Western patients
Abstract
Recent whole-genome sequencing showed frequent mutations of ARID1A in gastric cancer (GC). In this study of a large independent Central European cohort, we evaluated the expression of ARID1A in whole tissue sections (WTS) of GC testing the following hypotheses: ARID1A shows intratumoral heterogeneity, and ARID1A expression and/or heterogeneity correlates with clinicopathological patient characteristics. ARID1A expression was studied by immunohistochemistry in 450 primary GCs and 143 corresponding lymph node metastases. The expression pattern was correlated with clinicopathological characteristics and patient survival. ARID1A genotype and CpG methylation status were additionally analyzed in 7 GCs with a heterogeneous "black-and-white" expression pattern. ARID1A was expressed heterogeneously in 23 (5.1%) GCs, depicting a black-and-white pattern of negative and positive tumor areas. Complete loss of expression was found in 43 (9.6%) GCs. ARID1A status correlated significantly with tumor type according to Laurén, Epstein-Barr virus status, microsatellite instability, PD-L1 status, and nodal spread. There was no correlation with patient survival. In 4 cases with heterogeneous ARID1A expression, frame shift variants were detected. Summing up, heterogeneous or complete loss of ARID1A expression occurred in 14.7% of GCs and correlated with PD-L1 status, indicating potential for future combined anti-PD-L1/ARID1A therapy. In a subgroup of cases, ARID1A loss was heterogeneous, which suggests that ARID1A mutations might be a later event in gastric carcinogenesis.
Keywords: ARID1A; Gastric carcinoma; Heterogeneity; Immunohistochemistry; MSI; PD-L1.
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Comment in
-
Heterogeneity of ARID1A expression in gastric cancer may affect patient survival and therapeutic efficacy.Hum Pathol. 2020 Jul;101:80-81. doi: 10.1016/j.humpath.2020.04.009. Epub 2020 May 7. Hum Pathol. 2020. PMID: 32387347 No abstract available.
Similar articles
-
p53 immunostaining cannot be used to predict TP53 mutations in gastric cancer: results from a large Central European cohort.Hum Pathol. 2020 Nov;105:53-66. doi: 10.1016/j.humpath.2020.09.006. Epub 2020 Sep 22. Hum Pathol. 2020. PMID: 32971129
-
Clinicopathological features of tumor mutation burden, Epstein-Barr virus infection, microsatellite instability and PD-L1 status in Chinese patients with gastric cancer.Diagn Pathol. 2021 May 1;16(1):38. doi: 10.1186/s13000-021-01099-y. Diagn Pathol. 2021. PMID: 33933102 Free PMC article.
-
Functional loss of ARID1A is tightly associated with high PD-L1 expression in gastric cancer.Int J Cancer. 2019 Aug 15;145(4):916-926. doi: 10.1002/ijc.32140. Epub 2019 Feb 8. Int J Cancer. 2019. PMID: 30664822
-
Unique characteristics of ARID1A mutation and protein level in gastric and colorectal cancer: A meta-analysis.Saudi J Gastroenterol. 2017 Sep-Oct;23(5):268-274. doi: 10.4103/sjg.SJG_184_17. Saudi J Gastroenterol. 2017. PMID: 28937020 Free PMC article. Review.
-
ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.Cancer Lett. 2020 Mar 31;473:148-155. doi: 10.1016/j.canlet.2020.01.001. Epub 2020 Jan 3. Cancer Lett. 2020. PMID: 31911080 Review.
Cited by
-
Multiscale heterogeneity in gastric adenocarcinoma evolution is an obstacle to precision medicine.Genome Med. 2021 Nov 8;13(1):177. doi: 10.1186/s13073-021-00975-y. Genome Med. 2021. PMID: 34749812 Free PMC article.
-
SMARCA4 and SMARCE1 in gastric cancer: Correlation with ARID1A, and microsatellite stability, and SMARCE1/ERBB2 co-amplification.Cancer Med. 2023 May;12(9):10423-10437. doi: 10.1002/cam4.5776. Epub 2023 Mar 14. Cancer Med. 2023. PMID: 36916408 Free PMC article.
-
Landscape of EBV-positive gastric cancer.Gastric Cancer. 2021 Sep;24(5):983-989. doi: 10.1007/s10120-021-01215-3. Epub 2021 Jul 22. Gastric Cancer. 2021. PMID: 34292431 Review.
-
ARID1A Mutation May Define an Immunologically Active Subgroup in Patients with Microsatellite Stable Colorectal Cancer.Clin Cancer Res. 2021 Mar 15;27(6):1663-1670. doi: 10.1158/1078-0432.CCR-20-2404. Epub 2021 Jan 7. Clin Cancer Res. 2021. PMID: 33414133 Free PMC article.
-
Overview of Epstein-Barr-Virus-Associated Gastric Cancer Correlated with Prognostic Classification and Development of Therapeutic Options.Int J Mol Sci. 2020 Dec 10;21(24):9400. doi: 10.3390/ijms21249400. Int J Mol Sci. 2020. PMID: 33321820 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous